The purpose of this study is to find a dose of hydralazine that would be best to treat patient with ADPKD.
The study is 8 weeks long and will take place at the University of Kansas Medical Center.
Study visits will occur every 2 weeks for a total of 5 visits. All participants will receive the study medication (hydralazine) for a duration of 6 weeks.
Blood and urnine specimens will be collected at every study visit. Standard medical assessments will occur throughout the study.
- Adults between the age of 18-65 years of age
- Confirmed diagnosis of polycystic kidney disease (PKD)
- Liver disease
- Other exclusions may apply